GlassScriptPhysician profile
Molly A Sheron
NPI 1104896570
$2,638.81
in general payments reported to CMS, 2019-2025
28 companies · $880 in 2025
The $880 reported for 2025 was more than what 95% of Women'S Health (Nurse Practitioner) providers received nationally (typical 2025 total: $123).
See the full distribution for Women's Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $221 · 2022: $165 · 2023: $382 · 2024: $990 · 2025: $880.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,252.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,252.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $626.04 | 2021-2025 | |
| Novo Nordisk INC | $517.33 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $271.79 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| Exeltis, USA INC. | $177.99 | 2023-2025 | Slynd |
| Boehringer Ingelheim Pharmaceuticals, INC. | $132.79 | 2024-2025 | Jardiance, Synjardy, Tradjenta |
| Exact Sciences Corporation | $119.32 | 2024-2025 | Cologuard Collection Kit |
| Astellas Pharma US INC | $114.19 | 2023-2024 | Veozah |
| Pfizer INC. | $62.36 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $59.03 | 2022-2025 | |
| Grifols USA, LLC | $54.03 | 2025 | Prolastin-C Liquid |
| Amgen INC. | $52.82 | 2025 | Prolia, Evenity, Repatha |
| Millicent US INC | $48.00 | 2025 | Femlyv, Intrarosa |
| Phathom Pharmaceuticals, INC. | $47.05 | 2024-2025 | Voquezna |
| Hologic Sales and Service, LLC | $33.16 | 2021-2024 | Aptima |
| Organon LLC | $32.08 | 2023 | Nexplanon |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $29.56 | 2024 | Sapien 3 Ultra Resilia |
| Becton, Dickinson and Company | $27.98 | 2023 | |
| Coopersurgical, INC. | $27.60 | 2023 | Paragard T 380a |
| Pharmacosmos Therapeutics INC. | $27.12 | 2025 | Monoferric |
| Almatica Pharma LLC | $24.38 | 2024 | Teriparatide, Loreev Xr |
| Abbvie INC. | $24.19 | 2023 | |
| Agile Therapeutics, INC. | $21.75 | 2021 | |
| Merck Sharp & Dohme LLC | $21.37 | 2025 | Gardasil 9, Capvaxive |
| Alnylam Pharmaceuticals INC. | $18.87 | 2025 | Onpattro |
| Astrazeneca Pharmaceuticals LP | $18.49 | 2024 | Breztri |
| Novartis Pharmaceuticals Corporation | $18.30 | 2025 | |
| Janssen Scientific Affairs, LLC | $16.59 | 2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $14.63 | 2025 | Camzyos |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Molly Sheron listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.